Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres

Ryan K Shields; Emre Yücel; Vladimir Turzhitsky; Sanjay Merchant; Jae S Min; Alexandre H Watanabe

doi:10.1016/j.jgar.2024.03.002

Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres

J Glob Antimicrob Resist. 2024 Apr 6:37:190-194. doi: 10.1016/j.jgar.2024.03.002. Online ahead of print.

Authors

Ryan K Shields¹, Emre Yücel², Vladimir Turzhitsky³, Sanjay Merchant³, Jae S Min³, Alexandre H Watanabe³

Affiliations

¹ Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA.
² Merck & Co., Inc., Rahway, NJ. Electronic address: Emre.yucel@merck.com.
³ Merck & Co., Inc., Rahway, NJ.

PMID: 38588973
DOI: 10.1016/j.jgar.2024.03.002

Abstract

We assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support. The in-hospital mortality rate was 24%. These data advance our understanding of real-world indications and outcomes of imipenem/cilastatin/relebactam use.

Keywords: Complicated urinary tract infections; Gram-negative infection; Hospital-acquired/ventilator-associated bacterial pneumonia; Imipenem/cilastatin/relebactam.